CEO Executive AssistantPharmaceutical and biotech companies depend on specialized human capital more than almost any other industry. The scientists, clinicians, regulatory experts, commercial professionals, and manufacturing specialists who drive company value are difficult to recruit, expensive to retain, and organizationally devastating to lose at critical moments. Human resources is therefore not a back-office function for pharma CEOs; it is a strategic capability.
At the same time, the operational dimensions of HR, including recruiting logistics, benefits administration, compliance training management, payroll processing, and performance review scheduling, do not belong on the CEO’s desk. This guide establishes a delegation framework for pharma CEO human resources engagement that concentrates executive attention on strategic people decisions while building the HR organizational capacity to handle the full operational scope.
The CHRO as Strategic HR Delegate
The Chief Human Resources Officer is the CEO’s primary HR delegate and should be positioned as a genuine member of the senior leadership team with a voice in all strategic discussions. The CHRO’s mandate in a pharma organization is comprehensive: talent acquisition across all functional areas including scientific, clinical, commercial, and regulatory talent, compensation and benefits strategy, organizational development, performance management, leadership development, culture programs, compliance with employment law, and labor relations where applicable.
The CEO should engage with the CHRO on the strategic dimensions of each of these HR areas while delegating the operational execution fully. This means the CEO discusses talent strategy with the CHRO but does not manage the recruiting process; reviews compensation philosophy but does not set individual salaries below the executive level; participates in leadership development strategy but does not design training programs.
Delegating Scientific and Technical Talent Acquisition
Recruiting scientists, clinical researchers, and regulatory professionals in the pharmaceutical industry is a specialized function requiring deep knowledge of the talent market, competitive compensation intelligence, and the ability to evaluate technical credentials. This expertise should exist in the HR team, not in the CEO.
The VP of Talent Acquisition or Head of Scientific Recruiting owns the full talent acquisition process for scientific and technical roles: sourcing strategy, candidate evaluation, offer design within approved compensation ranges, and onboarding. For roles at the Director level and above, the relevant functional leader (CSO, CMO, Head of Regulatory Affairs) is the hiring manager and makes the selection decision. The CEO’s involvement is limited to approving VP-level and above hires after the functional leader recommendation.
The CEO may occasionally participate in candidate recruitment conversations for the most senior scientific or commercial hires, where CEO engagement signals organizational commitment and can tip a candidate’s decision. But these are bounded engagements, not full participation in the hiring process.
Compensation Strategy Delegation
Pharmaceutical compensation is complex: base salary, annual bonus, equity compensation, sign-on packages, retention awards, and benefits all play a role in attracting and retaining talent in a competitive market. Managing compensation at the organizational level requires both HR expertise and financial discipline.
The CHRO, in partnership with the CFO, should own compensation strategy: market benchmarking, pay band design, equity compensation philosophy, and benefits competitiveness. The CEO approves the overall compensation strategy and philosophy, reviews the annual compensation budget, and is the decision-maker for executive compensation. For all compensation decisions below the executive level, the CHRO has full authority within board-approved parameters.
A compensation committee of the board is typically responsible for approving CEO compensation and may review executive compensation more broadly. The CHRO prepares materials for this committee; the CEO presents their own compensation recommendations on behalf of the company and then recuses from board deliberations on their own pay.
Delegating Organizational Design
Organizational structure decisions in pharma, including how to organize R&D versus commercial functions, how to structure matrix versus functional hierarchies, and how to design new business unit or therapeutic area structures, are strategic decisions that the CEO influences strongly. But the organizational design analysis, options development, and implementation planning should be led by the CHRO with input from relevant functional leaders.
When a significant organizational design decision is needed, the CHRO should lead a design process that includes stakeholder input, options analysis, and an implementation plan, and then present recommendations to the CEO and leadership team. The CEO makes the strategic decisions; the CHRO designs and leads the implementation.
This process prevents organizational design from becoming an ad hoc CEO initiative that is implemented without adequate HR and change management expertise.
Managing Employee Relations at Scale
Employee relations in a pharma company encompasses a wide range of situations: individual workplace disputes, collective performance issues within teams, cultural concerns raised through engagement surveys, and in some markets, unionization dynamics. All of these require HR expertise and a consistent organizational approach.
The CEO’s appropriate employee relations role is: establishing the cultural standards and values that guide how employee relations issues are handled, receiving aggregate employee relations data (grievance volume, trends in employee relations issues, engagement survey results), and engaging personally when a significant cultural or values concern emerges that requires CEO-level response.
Individual employee relations situations, regardless of their sensitivity, should be managed by HR with the relevant manager. The CEO should not be personally involved in individual grievance investigations, performance management situations below the VP level, or individual termination decisions outside the C-suite.
The one exception is when an employee relations matter involves a senior leader whose situation has organizational-level implications. In these cases, the CEO works closely with the CHRO and legal counsel on the strategic management of the situation.
Leadership Development Delegation
Building the next generation of pharma leaders, including scientific leaders, commercial executives, and functional experts, is a CEO priority but not a CEO-managed activity. The CHRO should own the organization’s leadership development programs: succession planning processes, high-potential identification and development, executive coaching programs, and leadership curriculum.
The CEO’s leadership development role is: endorsing and personally championing the leadership development philosophy, participating in high-visibility development programs as a teacher or mentor, conducting annual talent reviews with the CHRO to discuss succession pipeline depth, and engaging personally with high-potential leaders the CHRO identifies as future C-suite candidates.
This bounded engagement is more effective than a CEO who tries to personally develop a large number of leaders without a structured program. The CHRO-led system ensures consistent development quality while the CEO’s personal engagement provides the organizational signal that leadership development is genuinely valued.
For context on how pharma leadership development connects to the clinical and commercial delegation structures, see pharma CEO clinical ops, which addresses how building strong clinical leadership capacity enables broader clinical delegation.
HR Technology and Analytics Delegation
Modern HR operations rely on HR information systems (HRIS), talent analytics platforms, learning management systems, and recruitment technology. Managing this technology stack is an operational HR function, not a CEO function.
The CHRO, in coordination with the CIO or IT function, owns HR technology strategy and operations. The CEO’s engagement is limited to approving significant HR technology investments and reviewing any material HR analytics findings that have strategic implications, such as significant retention risk in a critical talent population.
The HR analytics function should produce a quarterly people analytics report for the CEO covering: headcount and attrition by department, voluntary turnover trends, time-to-fill for critical roles, compensation competitiveness summary, and engagement survey results. This report gives the CEO strategic HR visibility without requiring direct involvement in HR operations or technology management.
According to Harvard Business Review research on strategic HR in pharma, pharmaceutical companies that position HR as a strategic business partner with operational independence significantly outperform those that treat HR as a purely administrative function. Delegating effectively to a CHRO-led HR organization is the structural mechanism that enables this strategic partnership.
See pharma CEO delegation guide for a comprehensive framework connecting HR delegation to the full range of pharma CEO organizational management responsibilities, including how people strategy connects to commercial and R&D organizational effectiveness.
The CEO’s Cultural Leadership Role
Beyond all operational HR delegation, the CEO retains an irreplaceable role as the primary cultural leader of the pharma organization. Culture in a pharmaceutical company, particularly the culture of scientific rigor, patient focus, compliance commitment, and ethical conduct, is set from the top. No amount of HR programming replaces the CEO’s daily modeling of the values the organization aspires to.
This cultural leadership role cannot be delegated to the CHRO, to the leadership team, or to any HR program. It is the CEO’s most important people-leadership contribution, and it requires the CEO to be present, intentional, and consistent in how they operate, communicate, and make decisions. Everything the CHRO and HR team do in programs and policies amplifies this foundation. Without it, HR programs build on sand.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.